Τόμος 20 (2002) – Τεύχος 1 – Άρθρο 1 – Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Ελληνική Έκδοση – Volume 20 (2002) – Issue 1 – Article 1 – Epitheorese Klinikes Farmakologias και Farmakokinetikes-Greek Edition

Γεώργιος Α. Κωνσταντινίδης, Βασίλειος Κόκκας, Λάζαρος Μπούτης

Εργαστήριο Φαρμακολογίας, Ιατρικό Τμήμα Αριστοτελείου Πανεπιστημίου Θεσσαλονίκης, Θεσσαλονίκη, Ελλάς

Georgios A. Konstantinidis, Basile Kokkas, Lazaros Boutis

Department of Pharmacology, Medical School, Aristotle’s University of Thessaloniki, Thessalo­niki, Greece

2. Toussis D., Antonitsis N., Boutis L.: Tamoxifen treatment of advanced cases of breast cancer. Internationa Meeting on Breast Cancer, Athens 1978, absrtract No 68

3. Kriaka A., Toliou T., Antonoglou O., Toussis D., Boutis L., Gabrielides C.: The effect oh hormone treatment and chemotherapy on estrogen receptors and on the histopa­thology of breast carcinoma. Mediterranean Cancer Con­ference, Cairo, 1980, abstract No 10

4. Boutis L.: New adjuvant therapies for operable breast cancer. Folia Oncologica 10: 87-91 (1988)

5. Boutis L.: Adjuvant chemotherapy and endocrine therapy of the operable breast cancer and chemotherapy and en­docrine therapy of advanced breast cancer. Ι.Ε.Θ. and Krikos, Thessaloniki, 1988

6. Boutis L.: Adjuvant endocrine therapy of operable breast cancer. In: Breast Cancer, ed European School of Oncol­ogy, pp. 194-203, 1990

7. Kotoula V., Karkavelas G., Sionga A., Economou L., Boutis L., Kerameos-Foroglou Chr.: Effects of tamoxifen and CV  205502 on the morphology and the evolution of the non-cancerous mouse mammary gland. Histol. Histo­pathol. 8: 627-636 (1993) (First price of the HSBCR for 1993)

8. Boutis L.: Pharmacological aspects of adjuvant treatment of early breast cancer with hormones and anti-hormones. In: (ESO ed.) Advances in Medical Oncology. Pp. 400-413, Thessaloniki, 1993

9. Boutis L., Kotoula V., Khazemzadech M., Antonoglou O., Kerameos –Foroglou Chr.: AACR 1995, abstract No 1849

10. Τούσης Δ.: Η θέση της ταμοξιφαίνης στην αντιμετώπιση του καρκίνου του μαστού. Ελληνική Ιατρική 49: 246-252 (1983)

11. Knight K.: Estrogen receptors as an independent prognostic factor for early recurrence of breast cancer. Cancer Res. 45: 223-232 (1977)

12. Κόκκας Β.: Πυρηνικοί υποδοχείς και φάρμακα. Επιστημονική Επετηρίδα Ιατρικού Τμήματος Αριστοτελείου Πανεπιστημίου Θεσσαλονίκης. Τόμος 28, 2001- δεκτό για δημοσίευση.

13. Bourget W., Germain P., Gronemayer H.Q: Nuclear receptor ligand binding domains. Three-dimensional struc­tures, molecular interactions and pharmacological implica­tions. Trends Pharmacol. Sci. 21: 381-382 (2000)

14. Bourne H., Roberts J.: Drug receptors and Pharmaco­dynamics. In: (Katzung B., ed.) Basic and Clinical Pharma­cology. Pp. 9-32, Prentice-Hall, Intrn.Inc. Con. USA 1995

15. Ross E.: Pharmacodynamics. In: (Hardman J. et al., eds) Goodman and Gilman’s”. The pharmacological Basis of Therapeutics. Pp. 29-41, McGraw-Hill Comp., New York,1996

16. Ruff M., Ganloff M., Wurtz M. Moras D.: Structure-func­tion relationship in DNA and ligand binding domains of estrogen receptors. Breast Cancer 2: 353-359 (2000)

17. Gustafson J.: An update on estrogen receptors. Semin Perinatol. 24: 66-69 (2000)

18. Stauffer S., Coletta C.,Tedesco R., Nishiguchi G., Carl­son K.: Pyrazol ligands. Stucture affinity/activity relation­ships and estrogen receptor alpha-selective agonists. J. Med. Chem. 43: 4934-4947 (2000)

19. Goldfien A.: The gonadal hormones and inhibitors. In: (Katzung B., ed.) Basic and Clinical Pharmacology. Pp. 608-636, Prentice-Hall, Intern. Inc. Con USA, 1995

20. Rinzler C.A.: Estrogen and Breast Cancer. Pp. 148-149, Hunter House, California, 1996

21. Fisher B., Constantino J., Redmond C., Poisson R., Bowman D., Couture J., et al.: A randomized clinical trial evaluating Tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N. Engl. J. Med. 320: 479-484 (1989)

22. Fisher B., Redmond C.: New perspective on cancer of the contralateral breast: a marker for assessing tamoxifen as a preventive agent. J. Natl. Cancer Inst. 83: 1278-1280 (1991)

23. Bernstein L., Ross R.K., Henderson B.E.: Prospects for the primary prevention of breast cancer. Am. J. Epidemiol­ogy 135: 142-152 (1992)

24. Rutqvist L.E., Mattson A.: Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in randomized trial of adjuvant tamoxifen. The Stockholm Breast Cancer Study Group. J. Natl. Cancer Inst. 85: 1398-406 (1993)

25. Medical Sciences Bulletin. Breast Cancer and the ta­moxifen Trials.

26. NIH Clinical Alert: Adjuvant Therapy of Breast Cancer-Tamoxifen Update.

27. Anderson C.: Science 263: 1679 (1994); Marshall E.: Science 264: 1524-1527 (1994)

28. Studies spark tamoxifen controversy. Science News, February 26, page 133, 1994

29. Kedar R.P., Bourne T.H., Powles T.J., Collins W.P., Ashley S.E., Cosgrove D.O., Campbell S.: Effects of ta­moxifen on uterus and ovaries of postmenopausal women in a randomized breast cancer prevention trial. Lancet 343: 1318-1321 (1994.)

30. Sherrill Sellman: Tamoxifen: A Major Medical mistake?” Nexus Magazine, Volume 5, #4 (June-July 1998)

31. Clorfene-Casten L., Breast Cancer: Poisons, Profits and Prevention. P. 93, Common Courage Press, Maine, USA, 1996

32. Bruning P.F., Bonfrer J.M., Hart A.A., de Jong-Bakker M., Linders D., van Loon J., et al.: Tamoxifen serum and cardiovascular risk. Br. J. Cancer: 497-499 (1988)

33. Fisher B., Constantino J.P., Redmond C.K., et al.: En­dometrial cancer in tamoxifen-treated breast cancer pa­tients: findings from the National Adjuvant Breast and Bowel Project (NSAPB-14). J. Natl. Cancer Inst. 86: 527-537 (1994)

34. Weed S.S.: Breast Cancer? P. 203, Breast Health!, Ash Tree Publishing, Woodstock, New York, 1996

35. Veronesi U., De Palo G., Costa A., Formelli F., Marubini E., Del Vecchio M.: Chemoprevention of Breast Cancer with Retinoid. J. Natl. Cancer Inst. Mogor 12: 93-97 (1992)

36. De Gregorio M., Wibe V.: Tamoxifen and Breast Can­cer, Yale University, USA, 1994

37. Early Breast Cancer Trialists Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy. Lancet 1: 1-15 and 17-85 (1992)

38. Austin S.N.D., Hitchcock C.: Breast Cancer: What You Should Know (But May Not Be Told) About Prevention, Diagnosis and Treatment. P. 102, Prima Publishing, Rock­lion, California, 1994

39. Everson R.B., et al.: Clinical correlations of steroid receptors and male breast cancer. Cancer Res. 40: 991 (1980)

40. Sellman S.: Hormone Heresy: What Women MUST Know About Their Hormones, Pp. 107-108, GetWell Inter­national, USA, 19974

41. http://cancertrials.nci.nih.gov/NCI_CANCER_TRIALS/zones/TrialInfo/News/star

42. http://cancertrials.nci.nih.gov/types/breast/prevention/star

43. Leppänen M., Kangas L.: Estrogenic and antiestrogenic effect of toremifene on rat and mouse uterus in vivo. Re­search report 1982. Orion Pharma, Data on file, 1992

44. Kallio S., Kangas L., Blanco G., Johansson R., Kar­jalainen A., Perilä M., Piippo I., Sundquist H., Södervall M., Toivola R.: A new triphenylethylene compound, Fc-117a. I. Hormonal effects. Cancer Chemother. Pharmacol. 17: 103-108 (1986)

45. Nieminen A.-L.: Antitumor effect of toremifene on MCF-7 breast cancer in vitro. Research report 23 July 1982. Orion Pharma, Data on file, 1981

46. Kangas L., Nieminen A.-L.: Effect of toremifene on primary endometrial cancer samples in vitro. Research report 2 May 1983. Orion Pharma, Data on file, 1983

47. Kangas L., Nieminen A.-L., Blanco G., Gronroos M., Kallio S., Karjalainen A., Perilä M., Södervall M., Toivola R.: A new triphenylethylene compound, Fc-1157a. II, Antitumor effects. Cancer Chemother. Pharmacol. 17: 109-113 (1986)

48. http://cancernet.nci.nih.gov/clinpdq/therapy/Questions_and_Answers_About_Tamoxifen.html

49. Shiuan C.: Aromatase and Breast Cancer, Division of Immunology, Beckman Research Institute of the City of Hope, Duarte, CA 91010, 1998

50. Μπούτης Λ.: Επιδημιολογία και θεραπευτικός αλγόριθμος θεραπείας καρκίνου του μαστού. Εις: Νεώτερες προσεγγίσεις στον προχωρημένο καρκίνο του μαστού. Πρακτικά Διεθνούς Συνάντησης, Θήρα, 1999

51. Μπούτης Λ.: Αναστολείς αρωματάσης Εις: (Γ. Κατσώχη) Χειρουργικές Παθήσεις του μαστού. Σελ. 301-305, Θεσσαλονίκη, 2000

52. Goss P.E., Yow O.: An overview of aromatase inhibitors in the treatment of metastatic breast cancer. Current On­cology 3: 1-9 (1999)

53. Bonneterre J., Buzdar A., Nabholz J.-M. Anastrozole is superior to tamoxifen as first line therapy in hormone receptor positive advanced breast carcinoma. Cancer 92: 2247-2258 (2001)

54. Lamb Harriet, Adkins J.: Letrozole. Drugs 56: 1125-1140 (1998)

55. Dombernowsky P., Smith I., Falkson G.: Letrozole, a new oral aromatase inhibitor for advanced breast cancer J. Clin. Oncol. 16: 453-461 (1998)

56. Mouridsen H., Gershanovich M., Sun Yan, Perez-Car­rion R.: Superior efficacy of letrozole versus tamoxifen as first line therapy for postmenopausal women with advanced breast cancer. J. Clin. Oncol. 19: 2596-2606 (2001)

57. Matthew E., Coop A., Mauriac L.: Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for erbB-1-and/orerbB-2 positive, estrogen receptor positive primary breast cancer. J. Clin. Oncol. 19: 3808-3816 (2001)

58. Geisler J., Anker G.: Letrozole suppresses plasma estrogen levels in postmenopausal breast cancer patients more completely than anastrozole ASCO abstracts  2000,  No 394

59. Thuerlimann B., Robertson J., Bonneterre J., Buzdar A.: Efficacy of tamoxifen following anastrozole as first line treatment for advanced breast cancer in postmenopausal patients. Eur. J. Cancer 37 (suppl 5): abstract  O-12 (2001)